User menu

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients)

Bibliographic reference Lepretre, Stephane ; Van Den Neste, Eric ; Aurran, Therese ; Mahe, Beatrice ; Cazin, Bruno ; et. al. Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine (FIT Cyclophosphamide (C) and MabCampath (Cam) (FCCam) in Previously Untreated Patients (pts) with Advanced B-Chronic Lymphocytic Leukemia (B-CLL) : Experience On Safety and Efficacy within a Randomised Multicenter Phase III Trial of the french Cooperative Group On CIA, and WM (FCGCLL/MW) and the "Groupe Ouest-Est d'Etudes Des Leucemies Aigues Et Autres Maladies Du sang" (GOELAMS): CLL2007FMP (for fit medically patients).51st Annual Meeting of the American-Society-of-Hematology (New Orleans (La), Dec 05-08, 2009). In: Blood, Vol. 114, no. 22, p. 225-225 (2009)
Permanent URL http://hdl.handle.net/2078.1/58588